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Abstract
Contrary to established wisdom, there now appear to be antibody-mediated central nervous system
(CNS) disorders. Over the last few years, a number of patients have been defined with antibodies to
voltage-gated (VGKC) or ligand-gated (NMDAR, GlyR) ion channels or ungated water (AQP4)
channels. Some of the disorders improve spontaneously over time, others may be more chronic and
relapsing-remitting, but immunotherapies reduce antibody levels and improve clinical outcomes.
These are exciting developments that herald a new era of immunotherapy-responsive CNS diseases,
and they raise interesting questions regarding the aetiological and pathogenic mechanisms mediating
these conditions.
Introduction and context
Autoimmune channelopathies are becoming one of the
exciting areas of neurological diseases in clinical practice
because, though relatively uncommon (collectively
perhaps 20 per million per year), diagnosis of these
conditions usually indicates a significant clinical
improvement following immunotherapies that reduce
autoantibody levels. The field stems from three decades
of research into myasthenia gravis and the Lambert-
Eaton myasthenic syndrome [1,2]; in these conditions,
autoantibodies to muscle nicotinic acetylcholine recep-
tors (AChRs) or voltage-gated calcium channels (P/Q-
type), respectively, are the main pathogenic agents and
cause destruction and/or downregulation of their targets,
leading to neuromuscular junction transmission failure
(Table 1) which can be demonstrated in animal models.
Newer disorders of peripheral neurotransmission
include (a) peripheral nerve hyperexcitability syndromes
with antibodies binding to
125I-dendrotoxin-labelled
shaker-type (Kv1) voltage-gated potassium channels
(VGKCs) extracted from mammalian cortex [3] and
(b) autonomic neuropathies with antibodies to
125I-epibatidine-labelled ganglionic nicotinic AChRs [4].
Over the last decade or so, a new family of antibody-
associated diseases has emerged that is beginning to
overturn previous concepts that regarded the brain as
immune-privileged and protected by an impermeable
blood-brain barrier. First, glutamate receptor (GluR3)
antibodies were present in children with the very rare but
devastating form of epilepsy called Rasmussen encepha-
litis [5], but these findings were not always confirmed in
other cohorts of patients [6], and the main pathology is
now thought to be cellular rather than antibody-driven
[7]. The paradigm shift really began with the finding of
very high VGKC antibody levels in patients with limbic
encephalitis – which includes seizures, psychological
disturbance, memory loss and high signal on magnetic
resonance imaging (MRI) in the medial temporal lobes –
who responded convincingly to immunotherapies such
as plasma exchange (which removes circulating plasma
components such as antibodies and replaces them with
substitute plasma proteins; see Figure 1) [8-10]. Until
then, limbic encephalitis was almost always recognised
as ‘paraneoplastic’ (that is, associated with a T cell-
mediated immune response to a tumour [11]) and
with a poor response to treatments. The VGKC
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notypes are now recognised widely, are usually nonpara-
neoplastic and include patients with some form of
epilepsy [12,13] or Morvan syndrome [14]. However,
despite colocalisation with antibodies to different Kv1
subtypes on brain tissue and in transfected HeLa cells
expressing different Kv1 subtypes, the specificity of the
antibodies is not altogether clear [15]; a new finding is
that many of the antibodies bind not to the Kv1s
themselves but to other juxtaparanodal proteins, such as
contactin-associated protein 2 (Caspr2), that form part
of the VGKC complex after extraction from brain tissue.
Antibodies to Caspr2 are particularly frequent in patients
with Morvan syndrome (S Irani, S Alexander, A Vincent,
unpublished data).
Major recent advances
Some patients presenting with symptoms of cognitive
problems, psychiatric disturbance or epilepsy were found
to have antibodies that bound to the proximal dendrites
of the hippocampal neuropil [16], distinct from the
binding of VGKC antibodies more distally [8,16];
many of these antibodies were subsequently shown to
be directed against N-methyl-D-aspartate receptors
(NMDARs) (NR1/NR2B) [17], with NR1 as the main
target [18]. Most of these patients progressed to a more
complex phenotype with movement disorders or cata-
tonia, mutism, sleep disturbance and autonomic dys-
function [17,18]. At first, the syndrome was associated
with ovarian teratomas in young women, but in these
cases, unlike the traditional paraneoplastic disorders
[11], the conditions improved when the tumour was
removed and immunotherapies given [17]. Now many
nonparaneoplastic cases are being identified and
the phenotype is widening to include both male and
female adults, teenagers, and even young children [18,19]
(S Irani, A Vincent, unpublished data). These NMDAR
antibodies may be different from those measured by
binding to linear peptide sequences of NR2A/NR2B seen
in neuropsychiatric patients [20] and have the potential
to be pathogenic since they target extracellular domains
on NR1/NR2B transfected human embryonic kidney
cells and substantially reduce the expression of these
subunits in primary cultures of hippocampal neurons
[18]. The NMDAR antibodies were most easily detected
in the cerebrospinal fluid (CSF) (at 1:10) compared with
serum (at 1:400), and there is substantial intrathecal
synthesis of the specific antibody [18] (Table 2); never-
theless, in absolute terms, serum levels are higher than
CSF levels. Recently, antibodies to AMPAR (a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor)
GluR1/GluR2 were identified in another form of limbic
encephalitis that was mostly cancer-related. These
patients also showed treatment responses but tended to
relapse [21].
Meanwhile, a completely different condition was found
to be associated with antibodies to a water channel.
Neuromyelitis optica (NMO, or Devic disease) has
usually been considered to be part of the spectrum of
inflammatory demyelinating disorders, of which multi-
ple sclerosis is the best known. However, NMO is a
distinct inflammatory condition of the optic nerves
which involves severe visual failure and inflammation of
the spinal cord causing longitudinally extensive trans-
verse myelitis (at least three spinal cord segments with
high signal on MRI), that leads to para- or tetraparesis,
sensory deficits and bladder disturbances. Patients show
variable recovery with immunomodulatory treatments
but accumulate disability over time, and mortality is
high if the disease is not appropriately treated [22]. In
2004, antibodies binding around small vessels, under
Table 1. Peripheral nervous system autoimmune channelopathies
Myasthenia gravis Lambert-Eaton myasthenic
syndrome
Peripheral nerve
hyperexcitability syndromes
Autonomic neuropathy
Typical symptoms Muscle weakness and fatigue Muscle weakness Muscle twitching, cramps, sweating Hypotension, constipation,
papillary abnormalities, sicca
syndrome (dry eyes and
mouth)
Target Muscle nicotinic AChR VGCC P/Q-type Dendrotoxin-binding VGKC Kv1.1,
1.2, 1.6 complexes extracted from
mammalian cortex
Ganglionic nicotinic AChR
(alpha 3)
Tumour association
or other pathology
Thymoma, thymic
hyperplasia or idiopathic
Small-cell lung cancer
common in adults (about 50%)
Thymoma, small-cell lung cancer
in about 20%
Small-cell lung cancer or
other tumours uncommon
Main pathogenic
mechanism
Complement-mediated
damage, increased AChR
degradation, some direct
block of AChR function
Increased VGCC degradation,
no evidence of complement-
mediated damage
Probably increased VGKC
degradation with no apparent
complement-mediated damage
Direct block of function and
increased degradation
Disease course Usually chronic, rare
spontaneous remissions
Usually chronic, may improve
with tumour removal
Can be chronic or monophasic,
postinfectious or postallergic
Monophasic or chronic,
postinfectious
AChR, acetylcholine receptor; VGCC, voltage-gated calcium channel; VGKC, voltage-gated potassium channel.
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by immunofluoresence [23], and the target was subse-
quently identified as aquaporin-4 (AQP4), the only
water channel expressed strongly in the brain (and also
in kidney and stomach) [24]. Antibodies to AQP4 bind
to the astrocyte endfeet that abut CNS blood vessels and
are thought to be important contributors to the integrity
of the blood-brain barrier. The antibodies lead to
substantial loss of surface AQP4 by internalisation and
activate complement with formation of the membrane
attack complex, leading to cellular damage [25]. They
also reduce astrocyte expression of excitatory amino acid
transporter 2 (EAAT2) with reduced reuptake of gluta-
mate [26] and hence potential excitotoxic damage.
Interestingly, it seems that AQP4 and EAAT2 are part of
a macromolecular complex [25]. Whether these changes
alone lead to the substantial inflammatory infiltrates,
areas of demyelination, loss of AQP4 and sometimes
necrosis that are found in lesions [27,28] is not yet
clear, but increases in antibody levels are asso-
ciated with clinical relapses, and AQP4 antibodies
decrease in parallel with clinical improvement after
Figure 1. Aspects of the new autoimmune channelopathies
(a) Above, magnetic resonance imaging evidence of hippocampal inflammation and swelling (arrows) in a patient with voltage-gated potassium channel
(VGKC) antibodies. Below, graph of dramatic decrease in the antibodies after successful treatment in another patient. (b) In the images above, antibodies
(red anti-human IgG) bind to human embryonic kidney cells expressing N-methyl-D-aspartate receptors (NMDARs) (coexpressed with enhanced green
fluorescent protein [EGFP]; some cells express EGFP without detectable NMDARs) in a young girl who developed an encephalopathy with mutism and
catatonia and made a complete recovery after immunotherapies (see [32] and the video available online). In the image below, NMDAR antibodies (green) bind
to unpermeabilised hippocampal neurons in culture, which were then fixed, permeabilised and stained for synaptophysin (blue) and NR1 (red) (the binding of
antibodies to the live cell surface does not colocalise well with the intracellular NR1 which appears throughout the neuron). (c) In the images above,
antibodies to aquaporin-4 (AQP4) in a patient with neuromyelitis optica (NMO) bind to cells transfected with AQP4-EGFP. In this case, the directly tagged
AQP4-EGFP can also be solubilised from the cells and, as seen in the graph, the antibodies can be measured quantitatively by counting the fluorescence in the
immunoprecipitates [34]. In these assays, sera from healthy individuals and from patients with unrelated diseases are negative. Ab, antibody; NDs, neurological
diseases. Images courtesy of S Irani, L Zuliani, MI Leite, P Waters and B Lang.
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doubt that the antibodies contribute to the pathology
[22].
Finally, another receptor target is emerging in patients
with rare spinal and brain stem syndromes. In one adult
male who presented with excessive startle and progres-
sive encephalomyelitis with rigidity and myoclonus
(PERM), a form of stiff person syndrome, antibodies to
glycine receptor alpha 1 pentamers (GlyR1s) were
identified [30]. The GlyR1 antibodies disappeared with
treatment and the patient made a substantial clinical
recovery. These antibodies are now being found in other
patients with related disorders (A Vincent, I Leite,
H-M Meinck, unpublished data).
Future directions
There are some important lessons that arise out of these
exciting advances. Once defined, the antibodies are best
identified by binding to native proteins extracted from
mammalian tissue in mild detergents (VGKCs), or better
still to the native protein expressed in an appropriate
human cell line (NMDARs, AMPARs, AQP4, GlyR),
rather than to short peptides that do not represent the
native conformation of the target antigen. The protein
must be expressed on the cell surface and the cells should
be unpermeabilised so that only cell surface-binding
antibodies are detected (this ensures that they are
potentially pathogenic, in contrast to those antibodies
to intracellular components found in paraneoplastic
disorders). Clustering of the antigen by use of intracel-
lular scaffolding proteins can increase sensitivity and
specificity as recently demonstrated for AChR antibodies
[31]. In addition, the antibodies should be shown to
bind to the extracellular surface of neurons or astrocytes
cultured from mammalian tissues and to induce relevant
biological changes in such cultures. In the future, one
hopes that these studies will extend to examining the
effects of these recently discovered antibodies on
neuronal activity in brain slices in vitro and in animal
models in vivo.
Considering the diversity of ion channels and receptors
in the nervous system, it would be strange if there were
no other autoimmune channelopathies to be discovered,
Table 2. Central nervous system autoimmune channelopathies
Examples VGKC-Ab-limbic
encephalitis
NMDAR-Ab
encephalitis
AMPAR-Ab encephalitis Neuromyelitis optica Glycine receptor anti-
body-associated disorder
Typical symptoms Memory loss, seizures,
psychiatric or psycho-
logical disturbance
Psychosis, bizarre
behaviours, mutism,
catatonia, movement
disorders, hypothalamic
dysfunction
Memory loss, confusion,
seizures, agitation
Sometimes downbeat
nystagmus
Optic nerve inflamma-
tion with visual loss
Spinalcordinflammation
leading to paralysis, loss
of sensation
Excessive startle, rigidity,
myoclonic jerks
Target Dendrotoxin-binding
CNS VGKC (Kv1.1,
1.2, 1.6)
NMDAR, probably
principally NR1
GluR1/2 dimers,
epitopes on GluR1 or
GluR2
AQP4 GlyR alpha 1a
Tumour association
or other pathology
Thymoma Ovarian teratomas in
young women
Breast cancer, small-cell
lung cancer, thymoma
Very rare Not common
Main pathogenic
mechanism
Increased
internalisation
Increased internalisation
Complement-mediated
mechanisms not
explored
Increased internalisation
Complement-mediated
mechanisms not
explored
Complement-mediated
mechanisms important
Increased internalisation
of AQP4 and increased
turnover of EAAT1 in
astrocytes
No evidence to date
Disease course Self-limiting in most
cases
Immunotherapies
hasten recovery and
reduce long-term
disability
Tumour cases do well
after removal and
treatments
Nontumour cases may
do less well and have a
tendency to relapse
Responds to
immunotherapies but
has tendency to relapse
Historically a severe
relapsing remitting dis-
ease with bad prognosis
May do better with
intensive
immunotherapies
First patient described
returned to work after
intense immunotherapies
Intrathecal synthesis
of specific antibody
Normal <1.5
a
1.5 to 40, variable but
sometimes high
10 to 30, High High Little or none (<1.5) 1.5 to >50, variable but
sometimes very high
aThis is calculated as (cerebrospinal fluid [CSF] titre of specific antibody/concentration of CSF IgG) / (serum titre of specific antibody/concentration of serum
IgG). Values above 1.5 are usually considered indicative of synthesis within the CSF compartment rather than the result of passive leakage. The values given
are based on our unpublished experience and from data presented in [18,21]. It needs to be appreciated that the normal serum IgG concentration is about
400 times higher than the normal CSF IgG concentration. Therefore, even in the presence of substantial intrathecal synthesis, the serum concentration
of specific antibody will be higher than the CSF concentration. Ab, antibody; AMPAR, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor;
AQP4, aquaporin-4; CNS, central nervous system; EAAT1, excitatory amino acid transporter 2; GluR, glutamate receptor; GlyR, glycine receptor; NMDAR,
N-methyl-D-aspartate receptor; VGKC, voltage-gated potassium channel.
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channels have been identified by a candidate approach,
but if the target for binding to the cultured cells is
sufficiently abundant, as appears to be the case for
AMPARs [21], it is possible to immunoprecipitate the
target using the relatively pure CSF IgG from the patients
[21]; this technique has potential for identifying new
targets in the future. Even the total patient plasma IgG
can be used to identify antigens by this approach when a
suitable cell preparation or cell line is identified [32].
In each of these diseases, CSF antibodies are found, and
there is often evidence of high concentrations of CSF-
specific antibody relative to CSF IgG concentration
when compared with similar measurements in serum
(‘intrathecal synthesis’, Table 2), but the absolute
concentration of antibody is still higher in serum than
in CSF. A major question, therefore, is whether the
antibodies that are pathogenic come directly from
the blood into the CNS parenchyma via a ‘leaky’ or
damaged blood-brain barrier or whether the disorders
require the presence of specific antibodies in the CSF.
The latter could be the result of passive diffusion
across the choroid plexus and/or intrathecal synthesis
by B cells that have gained entry to the CNS and
synthesise the antibodies in the intrathecal compart-
ment. These considerations are not purely academic.
Does intrathecal synthesis decrease with current
systemic treatments and increase if the patient
relapses? Do immune responses ever begin in the
CNS and remain undetectable in the serum? And
importantly, should drugs and therapies be specifically
targeted to the CSF compartment rather than to the
systemic immune system? These are just some of the
questions that arise from the identification of these
new autoimmune disorders, and the answers will
likely come from both focused human studies and
animal models.
Abbreviations
AChR, acetylcholine receptor; AMPAR, a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor;
AQP4, aquaporin-4; Caspr2, contactin-associated protein
2; CNS, central nervous system; CSF, cerebrospinal fluid;
EAAT2, excitatory amino acid transporter 2; GluR, gluta-
mate receptor; GlyR1, glycine receptor alpha 1 pentamer;
MRI, magnetic resonance imaging; PERM, progressive
encephalomyelitis with rigidity and myoclonus; NMDAR,
N-methyl-D-aspartate receptor; NMO, Neuromyelitis
optica; VGKC, voltage-gated potassium channel.
Competing interests
The author and her department receive royalties and
income for antibody immunoassays.
Acknowledgements
I am very grateful to my colleagues Sarosh Irani, Sian
Alexander, Luigi Zuliani, M Isabel Leite, Patrick Waters
and Bethan Lang for their helpful comments and for
providing their unpublished images and data for this
review.
References
1. Vincent A: Unravelling the pathogenesis of myasthenia gravis.
Nat Rev Immunol 2002, 2:797-804.
2. Vincent A, Lang B, Kleopa KA: Autoimmune channelopathies
and related neurological disorders. Neuron 2006, 52:123-38.
3. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O,
Morris C, Newsom-Davis J: Autoantibodies detected to
expressed K
+ channels are implicated in neuromyotonia.
Ann Neurol 1997, 41:238-46.
4. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA:
Autoantibodies to ganglionic acetylcholine receptors in
autoimmune autonomic neuropathies. N Engl J Med 2000,
343:847-55.
5. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K,
Crain B, Hughes TE, Heinemann SF, McNamara JO: Autoantibodies
to glutamate receptor GluR3 in Rasmussen’s encephalitis.
Science 1994, 265:648-51.
6. Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K,
Cross JH, Hart IK, Roubertie A, Valmier J, Hart Y, Palace J, Beeson D,
Vincent A, Lang B: Absence of antibodies to glutamate receptor
type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004,
63:43-50.
7. Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M,
Lassmann H, Mantegazza R, Villemure JG, Spreafico R, Elger CE:
Pathogenesis, diagnosis and treatment of Rasmussen
encephalitis: a European consensus statement. Brain 2005,
128:454-71.
8. Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M,
Vincent A: Potassium channel antibodies in two patients with
reversible limbic encephalitis. Ann Neurol 2001, 50:73-8.
9. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N,
Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J:
Potassium channel antibody-associated encephalopathy: a
potentially immunotherapy-responsive form of limbic ence-
phalitis. Brain 2004, 127:701-12.
10. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S:
Potentially reversible autoimmune limbic encephalitis with
neuronal potassium channel antibody. Neurology 2004, 62:1177-
82.
11. Dalmau J, Rosenfeld MR: Paraneoplastic syndromes of the CNS.
Lancet Neurol 2008, 7:327-40.
12. McKnight K, Jiang Y, Hart Y, Cavey A, Wroe S, Blank M, Shoenfeld Y,
Vincent A, Palace J, Lang B: Serum antibodies in epilepsy and
seizure-associated disorders. Neurology 2005, 65:1730-6.
13. Irani SR, Buckley C, Vincent A, Cockerell OC, Rudge P, Johnson MR,
Smith S: Immunotherapy-responsive seizure-like episodes
with potassium channel antibodies. Neurology 2008, 71:1647-8.
14. Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, Baruzzi A,
Carey T, Gambetti P, Lugaresi E, Montagna P: Morvan’s syndrome:
peripheral and central nervous system and cardiac involve-
ment with antibodies to voltage-gated potassium channels.
Brain 2001, 124:2417-26.
15. Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS: Neuromyo-
tonia and limbic encephalitis sera target mature Shaker-type
K
+ channels: subunit specificity correlates with clinical
manifestations. Brain 2006, 129:1570-84.
16. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A,
Houghton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J:
Treatment-responsive limbic encephalitis identified by
Page 5 of 6
(page number not for citation purposes)
F1000 Biology Reports 2009, 1:61 http://F1000.com/Reports/Biology/content/1/61neuropil antibodies: MRI and PET correlates. Brain 2005,
128:1764-77.
17. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A,
Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH,
Dichter MA, Rosenfeld MR, Lynch DR: Paraneoplastic anti-N-
methyl-D-aspartate receptor encephalitis associated with
ovarian teratoma. Ann Neurol 2007, 61:25-36.
F1000 Factor 3.0 Recommended
Evaluated by Angela Vincent 10 Apr 2007
18. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M,
Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR: Anti-
NMDA-receptor encephalitis: case series and analysis of the
effects of antibodies. Lancet Neurol 2008, 7:1091-8.
F1000 Factor 3.0 Recommended
Evaluated by Angela Vincent 24 Oct 2008
19. Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE, Rossi JE,
Bien CG: Diagnostic value of N-methyl-D-aspartate receptor
antibodies in women with new-onset epilepsy. Arch Neurol
2009, 66:458-64.
20. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT,
Diamond B: A subset of lupus anti-DNA antibodies cross-
reacts with the NR2 glutamate receptor in systemic lupus
erythematosus. Nat Med 2001, 7:1189-93.
F1000 Factor 3.0 Recommended
Evaluated by Angela Vincent 16 Jan 2002
21. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Matà S,
Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R,
Graus F, Lynch DR, Balice-Gordon R, Dalmau J: AMPA receptor
antibodies in limbic encephalitis alter synaptic receptor
location. Ann Neurol 2009, 65:424-34.
22. Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R,
Vincent A, Wildemann B: Mechanisms of disease: aquaporin-4
antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008,
4:202-14.
23. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF,
Fujihara K, Nakashima I, Weinshenker BG: A serum autoantibody
marker of neuromyelitis optica: distinction from multiple
sclerosis. Lancet 2004, 364:2106-12.
24. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR: IgG
marker of optic-spinal multiple sclerosis binds to the
aquaporin-4 water channel. J Exp Med 2005, 202:473-7.
F1000 Factor 3.0 Recommended
Evaluated by Angela Vincent 05 Oct 2005
25. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ,
Lennon VA: Pathogenic potential of IgG binding to water
channel extracellular domain in neuromyelitis optica. Neurol-
ogy 2007, 69:2221-31.
F1000 Factor 3.0 Recommended
Evaluated by Angela Vincent 18 Dec 2007
2 6 . H i n s o nS R ,R o e m e rS F ,L u c c h i n e t t iC F ,F r y e rJ P ,K r y z e rT J ,
Chamberlain JL, Howe CL, Pittock SJ, Lennon VA: Aquaporin-4-
binding autoantibodies in patients with neuromyelitis optica
impair glutamate transport by down-regulating EAAT2. J Exp
Med 2008, 205:2473-81.
F1000 Factor 3.0 Recommended
Evaluated by Charlotte Teunissen 06 Nov 2008
27. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S,
T a k a h a s h iT ,N a k a s h i m aI ,T a k a h a s h iH ,I t o y a m aY :Loss of
aquaporin 4 in lesions of neuromyelitis optica: distinction
from multiple sclerosis. Brain 2007, 130:1224-34.
28. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H,
Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM,
Lucchinetti CF: Pattern-specific loss of aquaporin-4 immunor-
eactivity distinguishes neuromyelitis optica from multiple
sclerosis. Brain 2007, 130:1194-205.
F1000 Factor 3.0 Recommended
Evaluated by Angela Vincent 04 Jun 2007
29. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T,
Lang W, Reindl M, Vincent A, Kristoferitsch W: Antibody to
aquaporin-4 in the long-term course of neuromyelitis optica.
Brain 2008, 131:3072-80.
30. Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S,
Connolly S, Hager H, Yu P, Becker CM, Vincent A: Progressive
encephalomyelitis, rigidity, and myoclonus: a novel glycine
receptor antibody. Neurology 2008, 71:1291-2.
31. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D,
Willcox N, Vincent A: IgG1 antibodies to acetylcholine
receptors in ‘seronegative’ myasthenia gravis. Brain 2008,
131:1940-52.
F1000 Factor 3.0 Recommended
Evaluated by Steven Burden 16 Jan 2009
32. Littleton E, Dreger M, Palace J, Vincent A: Immunocapture and
identification of cell membrane protein antigenic targets of
serum autoantibodies. Mol Cell Proteomics 2009, 8:1688-96.
33. Schimmel M, Bien CG, Vincent A, Schenk W, Penzien J: Successful
treatment of anti-N-Methyl-D-aspartate receptor encephali-
tis presenting with catatonia. Arch Dis Child 2009, 94:314-6.
34. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, Geraldes R,
Vale T, Jacob A, Palace J, Maxwell S, Beeson D, Vincent A: Aquaporin-4
antibodies in neuromyelitis optica and longitudinally extensive
transverse myelitis. Arch Neurol 2008, 65:913-9.
Page 6 of 6
(page number not for citation purposes)
F1000 Biology Reports 2009, 1:61 http://F1000.com/Reports/Biology/content/1/61